Keywords
Mal nutrition
Metabolism
Cannabidiol
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Analyze the physiology and histology of the duodenum, the effects of protein-energy malnutrition and the potentialities and therapeutic risks of cannabidiol. Literature review: This review addresses physiological, histological, and therapeutic aspects of the duodenum, nutrition, and the use of cannabidiol (CBD). It examines the duodenum's diminished role in nutrient digestion and absorption, highlighting structures such as Brunner's glands, villi, and microvilli, which are essential for mucosal protection and enhanced absorption. The effects of protein-energy malnutrition on fetal development are also discussed, including growth restriction and increased susceptibility to metabolic diseases in adulthood. CBD's interactions with the endocannabinoid system (CB1 and CB2), associated with anti-inflammatory, neuroprotective, and hepatoprotective effects, and its influence on energy homeostasis and the response to nutritional deficiency are explored. Final considerations: The study integrates physiological and histological knowledge of the duodenum, showing the effects of protein-energy malnutrition and the therapeutic potential of canabidiol, highlighting the role of the endocannabinoid system in energy homeostase and digestive health. There is a lack of conclusive clinical studies regarding the safety and hepatic toxicity of CBD in different doses, which restricts clinical practice.
References
ABRAHAMS JL, et al. Cannabidiol restores intestinal barrier function. Nutrients, 2021; 13: 3982.
ANAND U, et al. CBD inhibits and desensitizes neuronal TRPV1 signaling via inhibition of adenylyl cyclase and cAMP pathways: implications for pain modulation. J Pain Res., 2020; 13: 1251–63.
ALMEIDA RF, et al. Alterações morfológicas do duodeno. Rev Bras Cienc Vet., 2016; 23: 85–92.
BARKER DJP. Fetal origins of coronary heart disease. BMJ, 1995; 311: 171–4.
BARKER DJP. The origins of the developmental origins theory. J Intern Med., 2007; 261: 412–7.
CARVALHO RS, et al. Imunidade de mucosa e desnutrição proteica. J Bras Patol., 2020; 56: 134–41.
CANI PD, et al. Changes in gut endocannabinoid system tone. Diabetes, 2009; 58: 1718–26.
CRIPPA JAS, et al. Cannabidiol for the treatment of anxiety disorders. Neurotherapeutics, 2018; 15: 825–36.
CROZIER SJ, et al. Molecular mechanisms of pancreatic dysfunction induced by dietary protein deficiency. J Nutr Biochem., 2009; 20(9): 723–31.
COSTA B, et al. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of cannabidiol in a rat model of acute inflammation. Br J Pharmacol., 2004; 143(2): 247–50.
COSTA C, et al. Protein–energy malnutrition: mechanisms and clinical consequences in adults. J Nutr Intermediary Metab., 2021; 27: 100292.
CONFORTIM HD, et al. Maternal protein restriction during pregnancy and lactation affects the development of muscle fibers and neuromuscular junctions in rats. Muscle Nerve, 2017; 55(1): 109-115.
CORROON J e FELICE J. Consumer perceptions of cannabidiol. Cannabis Cannabinoid Res., 2019; 4: 152–9.
COUCH DG, et al. Cannabidiol ameliorates experimental colitis. Inflamm Bowel Dis., 2018; 24: 526–35.
DEVINSKY O, et al. Cannabidiol: pharmacology and therapeutic role. Epilepsia, 2014; 55: 791–802.
DESAI M, et al. Organ-selective growth in the offspring of protein-restricted mothers. Br J Nutr., 1996; 76(4): 591–603.
DI MARZO V, et al. Leptin-regulated endocannabinoids. Nature, 2001; 410: 822–5.
DUDELEA L, et al. Maternal protein restriction before pregnancy reduces offspring early body mass and affects glucose metabolism in C57BL/6JBom mice. J Dev Orig Health Dis., 2012; 3(5): 364–74.
ELANGO R e BALL RO. Protein and amino acid requirements during pregnancy. Adv Nutr., 2016; 7(5): 1006S–1012S.
ESPOSITO G, et al. Cannabidiol reduces intestinal inflammation through PPAR-γ. Mol Med., 2011; 17: 1–10.
FERNANDES ACS, et al. Cannabidiol: farmacologia e efeitos terapêuticos. Rev Bras Cienc Saúde, 2023; 19: 55–61.
GARIBOTTO G, et al. Muscle protein turnover and low-protein diets in patients with chronic kidney disease: mechanisms and adaptation. Nephrol Dial Transplant., 2020; 35(5): 741–8.
GENTON L, et al. Nutrition and gastrointestinal function. Clin Nutr., 2015; 34: 1–6.
GLUCKMAN PD e HANSON MA. Developmental origins of disease. N Engl J Med., 2008; 359: 61–73.
HASENOEHRL C, et al. Cannabinoids and gastrointestinal motility. Neurogastroenterol Motil., 2017; 29: e13149.
HOWLETT AC, et al. International Union of Pharmacology classification of cannabinoid receptors. Pharmacol Rev., 2002; 54: 161–202.
IFFLAND K e GROTENHERMEN F. Safety and side effects of cannabidiol. Cannabis Cannabinoid Res., 2017; 2: 139–54.
KEUSCH GT. The history of nutrition: malnutrition, infection and immunity. J Nutr., 2003; 133(1): 336S–40S.
KIRKHAM TC, et al. Endocannabinoids and feeding behaviour. Br J Pharmacol., 2002; 136: 550–7.
KOCH M, et al. Cannabinoid receptor signaling in central regulation of feeding behavior. Front Neurosci., 2017; 11: 293.
LANGLEY-EVANS SC. Nutritional programming of disease. Proc Nutr Soc., 2009; 68: 1–7.
LIMA APS, et al. Fitoterapia como estratégia complementar. Rev Saúde Coletiva, 2022; 32: 1–11.
LINARES IM, et al. Cannabidiol and neuroprotection. Neurochem Int., 2014; 75: 1–8.
LONG JZ, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol., 2009; 5(1): 37–44.
LU HC e MACKIE K. An introduction to the endogenous cannabinoid system. Biol Psychiatry, 2020; 79: 516–25.
MALAFAIA G. A desnutrição proteico-calórica como agravante da saúde de pacientes hospitalizados. ABC&HS, 2009; 34(2): 117–22.
MENEZES RC, et al. Alterações intestinais na desnutrição. J Pediatr., 2019; 95: 1–8.
MECHOULAM R e SHVO Y. The structure of cannabidiol. Tetrahedron., 1963; 19: 2073–8.
MORICONI A, et al. TRPV1 receptors and inflammation. Cell Mol Life Sci., 2020; 77: 1–12.
MÜLLER C, et al. Cannabinoid ligands targeting transient receptor potential channels and related mechanisms. Front Mol Neurosci., 2018; 11: 487.
NEJATBAKHSH F, et al. Cannabidiol in gastrointestinal diseases. Front Pharmacol., 2021; 12: 719–28.
OLIVEIRA JF, et al. Prevalência de desnutrição e risco nutricional em pacientes. Com. Ciências Saúde, 2014; 25(2): 157-172.
OTA E, et al. Antenatal dietary education and supplementation to increase energy and protein intake during pregnancy. Cochrane Database Syst Rev., 2015; CD000032.
O’SULLIVAN SE, et al. The peripheral cannabinoid receptor type 1 (CB1) as a molecular target for modulating body weight in humans. Molecules, 2021; 26(20): 6178.
PACHER P, et al. The endocannabinoid system as a therapeutic target. Pharmacol Rev., 2020; 72: 606–43.
PERTWEE RG. Cannabinoid pharmacology. Br J Pharmacol., 2006; 147(Suppl 1): S163–71.
PERTWEE RG. The diverse CB1 and CB2 receptor pharmacology. Br J Pharm., 2008; 153: 199–215.
PERTWEE RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol., 2015; 231: 1–37.
ROSEBOOM TJ, et al. Effects of prenatal exposure to famine. Lancet, 2006; 368: 44–52.
ROKEY AC, et al. Cannabinoids and the placenta: receptors, signaling and outcomes. Placenta, 2023; 60: 1–13.
RUSSO EB, et al. Cannabidiol in gastrointestinal disorders. Front Pharmacol., 2019; 10: 1–12.
SABIN CA, et al. Gastrointestinal mucosal atrophy in protein-calorie malnutrition. Arch Dis Child., 2006; 91(3): 272–7.
SANTOS JÚNIOR PL, et al. Pancreatic exocrine dysfunction induced by protein-energy malnutrition in rats: morphological and biochemical alterations. J Gastroenterol Hepatol., 2018; 33(5): 937–45.
SIDO JM, et al. Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. Int Rev Immunol., 2015; 34(5): 403-14.
SILVA RS, et al. Duodenal alterations in protein-energy malnutrition. Arq Gastroenterol., 2013; 50: 1–7.
SIMOPOULOS AP. Omega-6 and omega-3 fatty acids: Endocannabinoids, genetics and obesity. OCL – Oilseeds and Fats, Crops and Lipids, 2020; 27(8): 7.
SOUZA LP, et al. Insegurança alimentar e gestação. Rev Saúde Pública, 2020; 54: 1–9.
SWENSON KS, et al. Fetal cannabidiol (CBD) exposure alters neurodevelopment and postnatal behavior in mice. J Neurosci Res., 2023; 101(11): 2345–59.
TORRES N, et al. Protein restriction during pregnancy affects maternal liver lipid metabolism and fetal brain lipid composition in the rat. Am J Physiol Endocrinol Metab., 2010; 298(2): E270–7.
VICTORA CG, et al. Maternal and child undernutrition. Lancet, 2008; 371: 340–57.
WATERLAND RA e MICHELS KB. Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr., 2007; 27: 363–88.
WORLD HEALTH ORGANIZATION (WHO). Guidelines on the use of herbal medicines. Geneva: WHO; 2013.
WOLFF GL, et al. Epigenetic programming and metabolic disease. Endocrinology, 2018; 159: 1–10.
ZUARDI AW. Cannabidiol: from an inactive cannabinoid to a drug. Braz J Psychiatry, 2008; 30: 271–80.